Name | 1-(5-chlorothiophen-2-yl)sulfonyl-3-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1H-quinazolin-3-yl]phenyl]urea |
---|---|
Synonyms |
2-Thiophenesulfonamide, 5-chloro-N-[[[4-[6-fluoro-1,4-dihydro-7-(methylamino)-2,4-dioxo-3(2H)-quinazolinyl]phenyl]amino]carbonyl]-
5-Chloro-N-({4-[6-fluoro-7-(methylamino)-2,4-dioxo-1,4-dihydro-3(2H)-quinazolinyl]phenyl}carbamoyl)-2-thiophenesulfonamide Elinogrel UNII-915Y8E749J |
Description | Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet P2Y12 antagonist (IC50=20 nM). It is orally and intravenously available and has potent antiplatelet effects[1]. |
---|---|
Related Catalog | |
Target |
IC50: 20 nM (P2Y12)[2] |
References |
Density | 1.7±0.1 g/cm3 |
---|---|
Molecular Formula | C20H15ClFN5O5S2 |
Molecular Weight | 523.945 |
Exact Mass | 523.018738 |
PSA | 182.53000 |
LogP | 3.02 |
Index of Refraction | 1.706 |